Financial Performance - Q2 2025 - Revenue increased to $2.17 billion, a 20.1% increase compared to $1.81 billion in Q2 2024 [6, 7] - Gross Profit percentage improved to 23.5% compared to 20.1% in Q2 2024 [6, 7] - Earnings Per Share (EPS) rose to $6.53 per diluted share, a 74.6% increase from $3.74 in Q2 2024 [6, 7] - Cash Flow from Operations increased to $252.5 million, a 33% increase compared to $189.9 million in Q2 2024 [6] Financial Performance - YTD 2025 - Revenue reached $4.00 billion, a 19.6% increase compared to $3.35 billion for the same period in 2024 [9, 10] - Gross Profit percentage increased to 22.8% from 19.7% for the same period in 2024 [9, 10] - Earnings Per Share (EPS) was $11.28 per diluted share, a 75.4% increase compared to $6.43 for the same period in 2024 [9, 10] - Cash Flow from Operations was $164.5 million, a decrease compared to $336.4 million for the same period in 2024 [9] Backlog and Balance Sheet - Backlog increased to $8.12 billion compared to $6.89 billion in Q1 2025 and $5.77 billion in Q2 2024 [6] - Cash decreased to $331.7 million from $549.9 million as of December 31, 2024 [8]

In the latest close session, Veeva Systems (VEEV) was up +1.83% at $291.25. The stock's change was more than the S&P 500's daily gain of 0.07%. Meanwhile, the Dow experienced a drop of 0.7%, and the technology-dominated Nasdaq saw an increase of 0.18%. Heading into today, shares of the provider of cloud-based software services for the life sciences industry had gained 2.33% over the past month, lagging the Medical sector's gain of 2.39% and the S&P 500's gain of 5.71%.The upcoming earnings release of Veeva ...

West Pharmaceutical Services (WST 20.48%), a global manufacturer of drug packaging and delivery systems for the pharmaceutical and healthcare industries, reported Q2 2025 earnings on July 24, 2025. The key news was a significant beat on both GAAP revenue and non-GAAP EPS. Adjusted earnings per share (EPS) were $1.84, outpacing the $1.51 analyst estimate (non-GAAP). Revenue reached $766.5 million, surpassing GAAP expectations of $726.1 million. Management also raised its full-year 2025 outlook for both net s ...

Group 1 - Forterra has announced a formal partnership with Higher Ground to support veterans, first responders, and individuals with disabilities through therapeutic recreation and education [1][2] - The partnership aims to empower veterans by combining Forterra's advanced technology with Higher Ground's therapeutic programs, creating new opportunities for veterans to reconnect and recover [2][4] - Forterra's CEO emphasized the mission to reduce the impact of combat on humans and extend support beyond the battlefield through this partnership [3] Group 2 - Higher Ground has been active for over 25 years, focusing on transforming lives through therapeutic recreation and education, particularly for veterans and first responders [6] - The partnership includes sponsorship of events such as the fall 2025 Fly Fishing Week and aims to facilitate discussions on veteran well-being and transitions into fields like autonomy and defense technology [3][4] - Future initiatives will involve mentorship, technology exposure events, and co-branded service initiatives to enhance the lives of veterans and first responders [3]

IBM (IBM) came out with quarterly earnings of $2.8 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.06%. A quarter ago, it was expected that this technology and consulting company would post earnings of $1.42 per share when it actually produced earnings of $1.6, delivering a surprise of +12.68%.Over the last four quarters, ...

General Dynamics (GD) Q2 2025 Earnings Call July 23, 2025 09:00 AM ET Company ParticipantsNicole Shelton - VP - IRPhebe Novakovic - Chairman & CEOKimberly Kuryea - SVP & CFOJason Aiken - EVP - Combat & Mission SystemsM. Amy Gilliland - EVP & President - GDITDanny Deep - EVP - Global OperationsGautam Khanna - Managing DirectorSeth Seifman - Executive DirectorDouglas Harned - Managing DirectorScott Deuschle - Director - Aerospace & Defense Equity ResearchRobert Stallard - PartnerDavid Strauss - MD - Equity Re ...

COLUMBIA, Md., July 23, 2025 (GLOBE NEWSWIRE) -- Rekor Systems, Inc. (NASDAQ: REKR) ("Rekor "or the "Company"), a leader in developing and implementing state-of-the-art roadway intelligence technology, today announced that it will release its financial results for the second quarter of 2025 on Tuesday, August 12, 2025, after market close. On the same day, the Company will host its earnings conference call at 4:30 p.m. ET to discuss its financial and operating results. CONFERENCE CALL INFORMATION Any person ...

Core Insights - Alstom reported strong commercial performance in Q1 2025/26, with orders exceeding €4 billion and a positive outlook for future sales driven by North American momentum and projects in Germany [4][11]. Group Performance - Orders received in Q1 2025/26 amounted to €4.1 billion, an increase of 11.8% compared to €3.645 billion in the same period last year, with organic growth at 13.6% [3][6]. - Sales reached €4.5 billion, reflecting a 2.8% increase year-over-year, with organic sales growth of 7.2% [9][11]. Backlog and Future Visibility - As of June 30, 2025, Alstom's backlog stood at €92.3 billion, indicating strong visibility for future sales [2]. Geographic and Product Breakdown - Europe accounted for 85% of total order intake, with significant contracts including €1.7 billion for additional RER NG trainsets in France and €720 million for Coradia Stream trains in Bulgaria [7][8]. - In terms of sales, Rolling Stock generated €2.416 billion, up 3% reported and 5% organic, while Services reported stable sales of €1.070 billion [9][10]. Key Projects and Deliveries - Alstom delivered key milestones across various regions, including the first metro train for Grand Paris Express and the first Innovia automated people mover in the U.S. [12].

Company Performance - Doximity's stock (DOCS) decreased by 1.44% to $59.38, underperforming the S&P 500's daily gain of 0.06% [1] - Over the past month, Doximity's stock has increased by 3.92%, while the Medical sector has declined by 1.83% and the S&P 500 has risen by 5.88% [1] Earnings Forecast - Doximity is expected to release its earnings on August 7, 2025, with a forecasted EPS of $0.31, reflecting a 10.71% increase from the same quarter last year [2] - Revenue is projected to be $139.67 million, indicating a 10.26% growth compared to the corresponding quarter of the previous year [2] Full-Year Estimates - The Zacks Consensus Estimates for Doximity's full-year earnings are $1.46 per share and revenue of $625.72 million, representing year-over-year changes of +2.82% and +9.7%, respectively [3] - Recent adjustments to analyst estimates suggest evolving short-term business trends, with positive revisions indicating analyst optimism [3] Valuation Metrics - Doximity has a Forward P/E ratio of 41.3, which is higher than the industry average of 28.27 [6] - The company also has a PEG ratio of 4.48, compared to the Medical Info Systems industry's average PEG ratio of 3.23 [6] Industry Ranking - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 81, placing it in the top 33% of over 250 industries [7] - The Zacks Industry Rank is based on the average Zacks Rank of individual stocks within the industry, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...